Claims for Patent: 5,840,737

Summary for Patent: 5,840,737

Title:	Omeprazole solution and method for using same
Abstract:	A pharmaceutical composition includes an aqueous solution/suspension of omeprazole or other substituted benzimidazoles and derivatives thereof in a pharmaceutically acceptable carrier comprising a bicarbonate salt of a Group IA metal. A method for treating and/or preventing gastrointestinal conditions by administering to a patient a pharmaceutical composition including an aqueous solution/suspension of omeprazole or other substituted benzimidazoles and derivatives thereof in a pharmaceutically acceptable carrier including a bicarbonate salt of a Group IA metal wherein the administering step consists of a single dosage form without requiring further administering of the bicarbonate salt of the Group IA metal. A pharmaceutical composition for making a solution/suspension of omeprazole or other substituted benzimidazoles and derivatives thereof includes omeprazole or other substituted benzimidazoles and derivatives thereof and a bicarbonate salt of a Group IA metal in a form for convenient storage whereby when the composition is dissolved in aqueous solution, the resulting solution is suitable for enteral administration.
Inventor(s):	Phillips; Jeffrey Owen (Columbia, MO)
Assignee:	The Curators of the University of Missouri (Columbia, MO)
Application Number:	08/680,376
Patent Claims:	1. A method for treating gastric acid disorders by administering to a patient a single dose of a pharmaceutical composition of omeprazole or lansoprazole in a pharmaceutically acceptable carrier consisting essentially of a bicarbonate salt of a Group IA metal wherein said administering step consists of providing to the patient orally a single dose of an aqueous solution or, suspension of the pharmaceutical composition without requiring further administration of the bicarbonate salt of the Group IA metal. 2. A method according to claim 1, wherein the Group IA metal is sodium. 3. A method according to claim 1, wherein the Group IA metal is potassium. 4. A method according to claim 1, wherein the concentration of omeprazole in the composition range from approximately 0.5 mg/ml to approximately 6.0 mg/ml. 5. A method according to claim 3, wherein the concentration of omeprazole in said composition range from approximately 1.0 mg/ml to approximately 4.0 mg/ml. 6. A method as set forth in claim 5, wherein the concentration of omeprazole in the composition is approximately 2.0 mg/ml. 7. A method as set forth in claim 1, wherein the concentration of the bicarbonate salt of the Group IA metal in the composition ranges from approximately 5.0% to approximately 60.0%. 8. A method as set forth in claim 7, wherein the concentration of the bicarbonate salt of the Group IA metal in the composition ranges from approximately 7.5% to approximately 10.0%. 9. A method as set forth in claim 8, wherein the concentration of the bicarbonate salt of the Group IA metal is approximately 8.4%. 10. A method as set forth in claim 1, wherein the single dosage form includes a concentration of bicarbonate ranging from approximately 0.75 meq to 1.5 meq per milliliter. 11. A method as set forth in claim 10, wherein the amount of the bicarbonate in the single dosage form is less than approximately 12 mEq/20 mg dose of omeprazole. 12. A method as set forth in claim 1, wherein the single dosage form is administered in a volume of between approximately 10 ml and 20 ml.